SCHEMBL5481714

SCHEMBL5481714

Cc1ccc(C)c(C=C2C(=O)Nc3ccccc32)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.71
KMT2A Q03164 4/20 0.71
FLT3 P36888 5/20 0.59
KDR P35968 4/20 0.59
NPC1 O15118 3/20 0.59
CSF1R P07333 2/20 0.59
RET P07949 2/20 0.59
FGFR1 P11362 2/20 0.59
SRC P12931 2/20 0.59
FLT1 P17948 2/20 0.59
FGFR3 P22607 2/20 0.59
MAPK1 P28482 2/20 0.59
FLT4 P35916 2/20 0.59
ALK Q9UM73 2/20 0.59
PLK4 O00444 2/20 0.59
LMNA P02545 2/20 0.59
GMNN O75496 1/20 0.59
USP2 O75604 1/20 0.59
ABL1 P00519 1/20 0.59
PDGFRB P09619 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14448879 1.00 MEN1 (0.71) MEN1KMT2AFLT3KDRNPC1
SCHEMBL5481712 1.00 MEN1 (0.71) MEN1KMT2AFLT3KDRNPC1
SCHEMBL14448888 0.89 MEN1 (0.71) MEN1KMT2AFLT3KDRNPC1
SCHEMBL5470428 0.89 MEN1 (0.71) MEN1KMT2AFLT3KDRNPC1
SCHEMBL5470425 0.89 MEN1 (0.71) MEN1KMT2AFLT3KDRNPC1
SCHEMBL27743823 0.86 MEN1 (0.72) MEN1KMT2AFLT3KDRNPC1
SCHEMBL16427021 0.86 PLK4 (0.70) MEN1KMT2AFLT3KDRNPC1
SCHEMBL16427020 0.86 PLK4 (0.70) MEN1KMT2AFLT3KDRNPC1
SCHEMBL5476114 0.85 MEN1 (0.74) MEN1KMT2AFLT3KDRNPC1
SCHEMBL5476109 0.85 MEN1 (0.74) MEN1KMT2AFLT3KDRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
WO-2006105795-A1 NOVEL INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2006-10-12 WO disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 MEN1 1603/4885KMT2A 1891/4885FLT3 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.